Abivax S.A. | |
Stock Exchange | Euronext Paris |
EPS |
EUR1.57 |
Market Cap |
EUR76.58 M |
Shares Outstanding |
9.9 M |
Public Float |
5 M |
Address |
5, rue de la Baume Paris Ile-de-France 75008 France |
Employees | - |
Website | http://www.abivax.com |
Updated | 07/08/2019 |
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. |